



20 February 2009

**THE MANAGER  
COMPANY ANNOUNCEMENTS OFFICE  
ASX LIMITED**

Dear Sir/Madam

**Appointment of Dr Esra Ogru as Chief Operating Officer and  
Dr Paul Gavin as Vice President, Research & Development**

The Board of Directors of Phosphagenics Limited (ASX: "POH"; OTCQX: "PPGNY") is pleased to announce the appointment of executive director Dr Esra Ogru as Chief Operating Officer of the Company.

As a consequence of Dr Ogru's appointment, the Board of Directors is pleased to advise that Dr Paul Gavin has accepted the appointment to the position of Vice President of Research & Development to take over much of the role previously undertaken by Dr Ogru.

Dr Gavin is now responsible for the global coordination and management of the Company's pre-clinical and clinical research.

Dr Gavin will work with Phosphagenics' Scientific Advisors, in maintaining and enhancing the level of scientific rigor across the company's operations.

Since joining the Company in 2002, Dr Gavin has developed opportunities in both the Company's nutraceutical and pharmaceutical divisions such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management.

Prior to his joining Phosphagenics, Dr Gavin conducted research at Monash University's Department of Biochemistry and Molecular Biology.

Dr Gavin holds a Bachelor of Science (Hons) and a PhD in Biochemistry & Molecular Biology from Monash University, Melbourne. He is experienced in many aspects of academic and commercial research and development and has published in peer journals.

---

**Phosphagenics Limited**

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton Victoria 3168 Australia

Telephone: +61 3 9565 1119 Facsimile: +61 3 9565 1151

Web : [www.phosphagenics.com](http://www.phosphagenics.com) Email: [info@phosphagenics.com](mailto:info@phosphagenics.com)

## **Principal Place of Business**

The Company advises that it has now completed the re-location of its scientific and corporate administration staff to premises adjacent to Monash University in Clayton, Victoria:

Phosphagenics Limited  
Corporate and Research Laboratories  
11 Duerdin Street, Clayton, Victoria, 3168 Australia

Telephone: +61 (0)3 9565 1119  
Facsimile: +61 (0)3 9565 1151

Yours faithfully  
Phosphagenics Limited



Mourice R Garbutt  
Company Secretary  
p\asx\appointments\coa 20 02 09

### **About Phosphagenics Limited**

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

Phosphagenics' shares are listed on the Australian Stock Exchange (POH). An ADR – Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

For more information, please visit Phosphagenics' web site at [www.phosphagenics.com](http://www.phosphagenics.com)

**Safe Harbor Statement**

This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from the Phosphagenics' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations.

**Company Contact Details:**

Harry Rosen  
Phosphagenics Limited  
President and CEO  
+61 3 9565 1184

Dr Esra Ogru  
Phosphagenics Limited  
Chief Operating Officer  
+61 3 9565 1142

**U.S. Investor and Media Contacts:**

Brian Ritchie  
FD  
+1 212 850 5683